Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467584 · ClinicalTrials.gov registry record · Phase 3
Aspirin for Treatment of Multiple Sclerosis-Related Fatigue
A Phase 3 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT00467584: Clinical Trial Phase 3 study, sponsored by Mayo Clinic.
NCT00467584 is a Phase 3 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 62 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00467584, a Phase 3 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether aspirin is effective for treatment of fatigue caused by multiple sclerosis (MS).
Primary Outcome
The Modified Fatigue Impact Scale is a list of 21 statements describing how fatigue may affect a person's functioning. Answers ranging from 0 (Never) to 4 (Almost always) were provided by the study subjects for the prior 4 week period. A total score was tallied from a possible 0 (no fatigue impact) to 84 (almost always impacted by fatigue). A lower total score indicates less fatigue-related impact while a higher total score indicates greater fatigue-related impact on a subject's functioning.
Interventions
- DRUG Placebo
- DRUG High Dose Aspirin (1300 mg/day)
- DRUG Low Dose Aspirin (162 mg/day)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2007-07 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Why NCT00467584 stopped before completion
NCT00467584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00467584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00467584 about?
NCT00467584 is a clinical study titled "Aspirin for Treatment of Multiple Sclerosis-Related Fatigue". The purpose of this study is to determine whether aspirin is effective for treatment of fatigue caused by multiple sclerosis (MS).
What is the current status of trial NCT00467584?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2007-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00467584?
The interventions under investigation include: Placebo (DRUG), High Dose Aspirin (1300 mg/day) (DRUG), Low Dose Aspirin (162 mg/day) (DRUG).
Who is sponsoring clinical trial NCT00467584?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00467584's enrollment target sits among peer trials
62 1802nd of 2000 higher than 198 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia